Molecular Markers of Sensitivity to the Anticancer Effects of Different Statins in Human Tumour Cell Lines

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  2014-06-20

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The tumor microenvironment is a dominant force in multidrug resistance.

  2012influential reference
• MYC on the path to cancer.

  2012cited by this paper
• Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization

  2012cited by this paper
• Collateral sensitivity as a strategy against cancer multidrug resistance.

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Regulation of gene transcription by the oncoprotein MYC.

  2012cited by this paper
• Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012influential reference
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• P53 and its molecular basis to chemoresistance in breast cancer

  2012cited by this paper
• Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

  2012cited by this paper
• Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.

  2012cited by this paper
• Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: A retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry

  2012cited by this paper
• Dissecting the heterogeneity of triple-negative breast cancer.

  2012influential reference
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012influential reference
• Drug development and clinical trials—the path to an approved cancer drug

  2012cited by this paper
• Drug resistance in the mouse cancer clinic.

  2012influential reference
• From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma.

  2012influential reference
• Targeting tumor cell metabolism with statins

  2012cited by this paper
• Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity.

  2012cited by this paper
• Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

  2012cited by this paper
• Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

  2012cited by this paper
• Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

  2012cited by this paper
• Gene profiling assay and application: the predictive role in primary therapy.

  2011influential reference
• A gene expression signature identifies two prognostic subgroups of basal breast cancer

  2011cited by this paper
• Targeting protein prenylation for cancer therapy

  2011influential reference
• Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

  2011cited by this paper
• Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity

  2011cited by this paper
• Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification

  2011influential reference
• Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor γ2 Expression

  2011cited by this paper
• Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites

  2011cited by this paper
• mRNA transcript quantification in archival samples using multiplexed, color-coded probes

  2011cited by this paper
• The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action

  2011cited by this paper
• Quantifying factors for the success of stratified medicine

  2011cited by this paper
• RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis

  2011cited by this paper
• Use of standard markers and incorporation of molecular markers into breast cancer therapy

  2011cited by this paper
• Pooled lentiviral shRNA screening for functional genomics in mammalian cells.

  2011cited by this paper
• Analysis of the Mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer

  2011cited by this paper
• COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines

  2011cited by this paper
• Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

  2011cited by this paper
• Subtype and pathway specific responses to anticancer compounds in breast cancer

  2011cited by this paper
• The value of genomic analysis of breast cancer in drug development.

  2011cited by this paper
• High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation

  2010influential reference
• Statins can modulate effectiveness of antitumor therapeutic modalities

  2010cited by this paper
• Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance

  2010influential reference
• Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.

  2010cited by this paper
• Dysregulation of the mevalonate pathway promotes transformation

  2010influential reference
• Metabolomic analysis via reversed-phase ion-pairing liquid chromatography coupled to a stand alone orbitrap mass spectrometer.

  2010cited by this paper
• Genomic index of sensitivity to endocrine therapy for breast cancer.

  2010cited by this paper
• Statin use and cancer risk: a comprehensive review

  2010cited by this paper
• Lipidomics: a mass spectrometry based systems level analysis of cellular lipids.

  2009cited by this paper
• CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.

  2009cited by this paper
• Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

  2009cited by this paper
• Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

  2009cited by this paper
• An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ

  2009cited by this paper
• Genes that mediate breast cancer metastasis to the brain

  2009cited by this paper
• The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

  2009cited by this paper
• Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

  2009cited by this paper
• In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model

  2008cited by this paper
• Enabling personalized cancer medicine through analysis of gene-expression patterns

  2008cited by this paper
• The humoral immune system has a key prognostic impact in node-negative breast cancer.

  2008cited by this paper
• Differences in antitumor effects of various statins on human pancreatic cancer

  2008cited by this paper
• Direct multiplexed measurement of gene expression with color-coded probe pairs

  2008cited by this paper
• Comparative evaluation of the effects of statins on human stem and cancer cells in vitro.

  2007cited by this paper
• The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.

  2007influential reference
• High dose Simvastatin does not reverse resistance to Vincristine, Adriamycin, and Dexamethasone (VAD) in Myeloma

  2007cited by this paper
• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  2007cited by this paper
• Modelling breast cancer: one size does not fit all

  2007influential reference
• Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro

  2007cited by this paper
• Oncogenic pathway signatures in human cancers as a guide to targeted therapies

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies

  2006cited by this paper
• Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

  2006cited by this paper
• Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.

  2006influential reference
• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  2006cited by this paper
• Breast cancer growth prevention by statins.

  2006cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

  2006cited by this paper
• Gene Expression Profiling in Cervical Cancer: An Exploration of Intratumor Heterogeneity

  2006cited by this paper
• A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

  2006cited by this paper
• Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.

  2005cited by this paper
• Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

  2005influential reference
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.

  2005cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005influential reference
• Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

  2003cited by this paper
• Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells

  2003cited by this paper
• Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001influential reference
• Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.

  2001cited by this paper
• Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells.

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000influential reference
• c-Myc in breast cancer.

  2000cited by this paper
• A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme.

  1998cited by this paper
• A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.

  1997cited by this paper
• Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

  1996cited by this paper

• No citing papers are available for this paper.